Sharp Therapeutics Corp.
SHRXF
$1.58
-$0.08-4.81%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 111.09% | -22.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 65.84% | -27.70% | |||
| Operating Income | -65.84% | 27.70% | |||
| Income Before Tax | -120.46% | -294.15% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -120.46% | -294.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -120.46% | -294.15% | |||
| EBIT | -65.84% | 27.70% | |||
| EBITDA | -66.30% | 27.90% | |||
| EPS Basic | -137.85% | -292.55% | |||
| Normalized Basic EPS | -138.05% | -291.53% | |||
| EPS Diluted | -138.95% | -292.55% | |||
| Normalized Diluted EPS | -138.05% | -291.53% | |||
| Average Basic Shares Outstanding | -7.26% | 1.05% | |||
| Average Diluted Shares Outstanding | -7.26% | 1.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||